SAN 903
Alternative Names: SAN-903Latest Information Update: 16 Mar 2025
At a glance
- Originator Saniona
- Class Anti-inflammatories; Antifibrotics; Irritable bowel syndrome therapies
- Mechanism of Action Intermediate conductance calcium activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Fibrosis; Haematological disorders; Inflammatory bowel diseases
Most Recent Events
- 05 Mar 2025 Preclinical development in Inflammatory-bowel-diseases is ongoing in Denmark
- 28 Mar 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Denmark
- 28 Mar 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Denmark